Ryzneuta

Active Ingredient(s): Efbemalenograstim Alfa-vuxw
FDA Approved: * November 16, 2023
Pharm Company: * EVIVE BIOTECHNOLOGY
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ryzneuta 20 mg/ml Subcutaneous Injection
NDC: 73491-627
Labeler:
Evive Biotechnology Singapore Pte. Ltd.